Home
/

What is a Fructosamine Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

Fructosamine measures glycated serum proteins (mainly albumin) formed when glucose binds amino groups, reflecting average blood glucose over the past 2–3 weeks—shorter than HbA1c's ~3-month window. Normal range is roughly 200–285 µmol/L; elevated levels are associated with recent hyperglycemia and glycation stress on vessels, kidneys, nerves, and eyes, while low values may reflect low glucose or low albumin from liver disease, nephrotic syndrome, or hyperthyroidism. It's especially useful when HbA1c is unreliable and may help support tracking of rapid glycemic changes during pregnancy or after medication adjustments.

Read more →
Table of contents

Fructosamine: glycated proteins as a two-to-three-week glucose memory

Fructosamine is the collective signal of sugars attached to blood proteins. In the bloodstream, glucose binds spontaneously to free amino groups on circulating proteins—mostly albumin—through nonenzymatic glycation (Maillard reaction), forming stable ketoamine adducts (fructosamines). A fructosamine blood test quantifies these glycated serum proteins, so the biomarker originates from the everyday interaction between glucose and the body’s protein pool in serum.

Its significance is that it reflects your recent average glucose exposure over a short window. Because serum proteins like albumin turn over quickly, fructosamine captures the prior few weeks of glycemia rather than long-term history. It summarizes the body’s “recent sugar imprint” on proteins, smoothing out day-to-day swings to show cumulative exposure over that period. This makes it a complementary marker to glycated hemoglobin (HbA1c), offering a nearer-term view that does not depend on red blood cells. In essence, fructosamine tells the story of how much glucose your circulating proteins have encountered lately.

What recent average glucose exposure reveals about metabolic health

Fructosamine reflects how much of your circulating proteins—mainly albumin—have been sugar-coated, capturing your average blood glucose over the last 2–3 weeks. It shows how intensely glucose has been bathing your tissues in the near term, which matters for vessels, nerves, eyes, kidneys, and healing. It’s especially useful when A1c is unreliable (anemia, hemoglobin variants, recent transfusion, pregnancy) or when you need to see change quickly.

Big picture, fructosamine links glucose exposure to protein biology. It complements A1c and glucose logs, and its trend—alongside albumin, thyroid function, and kidney/liver status—helps forecast microvascular risk and guide safer, steadier metabolic health.

How low, in-range, and high fructosamine values typically read

Most labs consider a typical reference range roughly 200 to 285, with “healthy” values tending toward the middle. Because fructosamine depends on both glucose and protein turnover, interpretation works most appropriate in context of albumin and thyroid status.

When values run low, it can mean average glucose has been low—often with shakiness, sweating, hunger, or confusion from hypoglycemia. It can also signal fewer or shorter‑lived serum proteins, as in liver disease, nephrotic protein loss, hyperthyroidism, or late pregnancy dilution; here you might see swelling, fatigue, or other signs of protein deficit. Men and women are generally similar; pregnancy lowers values for a given glucose level.

When values are high, it points to sustained hyperglycemia over recent weeks—thirst, frequent urination, fatigue, blurred vision—and increased glycation stress on small vessels and nerves. Slower protein turnover (hypothyroidism), steroids, or Cushing physiology can amplify elevations. In teens or pregnancy, it helps flag short‑term control issues and gestational diabetes.

Low values usually reflect either lower recent glucose levels or fewer/shorter‑lived circulating proteins. They can occur with tight glucose control or hypoglycemia, but more often with low albumin from pregnancy, liver disease, kidney protein loss, or faster protein turnover such as in too much thyroid hormone (hyperthyroidism). In these settings, a low fructosamine may not mean low glucose.

Being in range suggests stable day‑to‑day glucose exposure and normal protein turnover. In many labs, values in the low‑to‑middle part of the reference interval correspond to normoglycemia and lower short‑term glycation burden.

High values usually reflect sustained higher glucose over the prior 2–3 weeks, leading to more sugar‑coated proteins (nonenzymatic glycation). This signals increased oxidative and inflammatory stress on small vessels and is common with diabetes, including gestational diabetes, and with medicines that raise glucose such as glucocorticoids. Slower protein turnover—too little thyroid hormone (hypothyroidism) or chronic kidney disease—can also raise fructosamine independent of glucose.

Albumin status, protein turnover, and assay considerations

Interpretation depends on protein status and assay. Low or changing albumin, pregnancy, nephrotic syndrome, liver disease, or IVIG can shift results; albumin‑corrected fructosamine or glycated albumin can help. Unlike A1c, red‑cell disorders have little effect. Very high vitamin C, bilirubin, or lipemia may interfere with some assays.

Fructosamine is most useful read alongside A1c and fasting or postprandial glucose. The combination separates recent average exposure (last 2–3 weeks) from longer-term glycation patterns and current control, helping track treatment changes in pregnancy or hemoglobin variants.

FAQs

Fructosamine is a compound formed when glucose attaches to blood proteins, mainly albumin, through a process called glycation. It reflects the average blood sugar level over the past two to three weeks, as serum proteins have a shorter lifespan than red blood cells. By measuring the amount of glycated proteins in the blood, fructosamine provides a snapshot of recent glycemic control, making it a valuable tool for tracking short-term changes in blood sugar, especially when rapid adjustments in diabetes management are needed.

Fructosamine testing measures the glycation of serum proteins, primarily albumin, reflecting average blood glucose over the previous 2–3 weeks. In contrast, hemoglobin A1c (HbA1c) measures glycation of red blood cells, representing average glucose over 2–3 months. Fructosamine is more sensitive to recent changes in glucose control and is not affected by conditions that alter red blood cell turnover, such as anemia or recent transfusions, making it useful when A1c results may be unreliable.

Fructosamine testing is especially useful when rapid feedback on blood sugar control is needed, such as after starting or adjusting diabetes medications, during pregnancy, or when A1c results are unreliable due to anemia, hemoglobin variants, or recent blood transfusions. It helps guide insulin or medication titration, track trends between A1c checks, and clarify recent high blood sugar episodes that may cause symptoms like thirst, fatigue, or frequent urination.

Most labs consider fructosamine values between 200–285 µmol/L as typical. Values in the mid-range suggest stable, normal glucose control. High fructosamine indicates recent hyperglycemia, which can increase the risk of complications like vascular, nerve, kidney, and eye damage. Low values may reflect low recent glucose, but can also result from low or rapidly turning over serum proteins due to conditions like malnutrition, liver disease, kidney protein loss, or hyperthyroidism, potentially underestimating true glycemia.

During pregnancy, physiological changes such as hemodilution can lower albumin levels, making A1c less reliable for short-term glucose monitoring. Fructosamine provides a more immediate measure of glycemic control over the past 2–3 weeks, helping to guide treatment adjustments and helps support within reference ranges outcomes for both mother and baby when rapid changes in blood sugar management are required.

Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

References

  1. Danese, E., Montagnana, M., Nouvenne, A., & Lippi, G. (2015). Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. Journal of Diabetes Science and Technology, 9(2), 169-176. https://doi.org/10.1177/1932296814567227
  2. Cohen, R. M., & Smith, E. P. (2008). Frequency of HbA1c discordance in estimating blood glucose control. Current Opinion in Clinical Nutrition and Metabolic Care, 11(4), 512-517. https://doi.org/10.1097/MCO.0b013e32830467bd
  3. American Diabetes Association Professional Practice Committee. (2024). 6. Glycemic goals and hypoglycemia: Standards of care in diabetes-2024. Diabetes Care, 47(Suppl. 1), S111-S125. https://doi.org/10.2337/dc24-S006
  4. American Diabetes Association Professional Practice Committee. (2024). 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. Diabetes Care, 47(Suppl. 1), S20-S42. https://doi.org/10.2337/dc24-S002
  5. Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ, 321(7258), 405-412. https://doi.org/10.1136/bmj.321.7258.405

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey